Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-3195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review.
Reumatismo
January 2025
Unit of Dermatology, Department of Medicine and Aging Science, G. d'Annunzio University, Chieti.
Objective: Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies.
Methods: An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline.
Effectiveness, quality of life, and safety of secukinumab versus conventional systemic therapy in patients with erythrodermic psoriasis: a comparative study.
Front Med (Lausanne)
November 2024
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, Jiangsu, China.
Background: Erythrodermic psoriasis (EP) is a rare but life-threatening variant of psoriasis less responsive to conventional systemic therapies (CST). Limited research exists on the management of EP with secukinumab.
Objectives: To compare the effectiveness, quality-of-life effects and safety of secukinumab versus CST in patients with EP.
Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers.
J Pers Med
November 2024
Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, 50134 Florence, Italy.
Article Synopsis
- The study evaluated the effectiveness and retention rate of secukinumab (SCK) in patients with axial spondyloarthritis (ax-SpA) using data from five Italian centers.
- A total of 71 patients were analyzed, showing significant improvements in disease activity over 24 months, with BASDAI scores decreasing from 6.2 to 3.5 and ASDAS-CRP from 2.9 to 1.7.
- Though 72% of patients remained on SCK after two years, those with fibromyalgia had a higher dropout rate, indicating that coexisting conditions may affect treatment adherence.
Psoriasis Flare Following Paramyxovirus Infection.
Psoriasis (Auckl)
November 2024
Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
Psoriasis is a chronic, immunologically mediated disease of multifactorial origin, with genes playing a key role and environmental factors, such as infections, often triggering its onset or exacerbation. While acute streptococcal infections are commonly linked to guttate psoriasis, viral and fungal infections have also been associated with psoriasis flares. We report a case of severe psoriasis exacerbation during viral parotitis caused by paramyxovirus in a 49-year-old male patient with a long-standing psoriasis diagnosis.
View Article and Find Full Text PDFPurpose Of Review: There have been advances in the diagnosis and treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
Recent Findings: Themes in PMR and GCA include classification criteria, ultrasound imaging of temporal and axillary arteries replacing biopsies for diagnosis of GCA, faster diagnosis and treatment with rapid access clinics for suspected GCA, and expanding treatment options with the goal of rapid suppression of inflammation and sparing steroids.
Summary: Treatment is aimed at suppressing inflammation quickly in both GCA and PMR.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!